Samsung’s partner, Biogen files patent infringement trial against Celltrion
Biogen Idec, the patentee of Mabthera(foreign name: Rituxan), applied for a judgment for the patent infringement against Celltrion.
Biogen is not only the second largest shareholder holding 9.7% of the entire Samsung Bioepis’ stocks, but a European partner that Samsung developed for biosimilars....
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
